proLékaře.cz | 6.10.2026

22. Keating MJ, O'Brien S, Albitar M, Lerner S, Wierda W, Kantarjian H. Extended follow-up of chemo-immunotherapy regimen FCR (fludarabiune, F; cyclophosphamide C and rituximab R) as initial therapy for chronic lymphocytic leukemia (CLL). Blood 2005; 106: 599a [abstrakt 2118].
23. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98(12): 2657–63.
24. Wendtner CM, Ritgen M, Schweighofer CD, et al. German CLL Study Group (GCLLSG). Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18(6): 1093–101.
25. Del Poeta G, Del Principe MI, Consalvo MA, et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer 2005; 104(12): 2743–52.
26. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24(15): 2337–42.
27. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001; 15(3): 445–51.
28. Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104(8): 2600–2.
29. Moreno C, Villamor N, Colomer D, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107(11): 4563–9.
30. Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008; 112(1): 119–28.
31. Nabhan C, Coutré S, Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Br J Haematol 2007; 136(3): 379–92.
32. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008; [Epub ahead of print].
33. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87(12): 4990–7.

MUDr. Ludmila Bezdíčková
Oddělení klinické hematologie FN Královské Vinohrady
Šrobárova 50
100 34 Praha 10

Došlo do redakce: 8. 4. 2008
Přijato: 27. 5. 2008

OSOBNÍ ZPRÁVY

Prof. BLAHOŠ – důstojník Řádu Čestné legie

Dne 23. června 2008 převzal prof. MUDr. Jaroslav Blahoš, DrSc. z rukou velvyslance Francie J. E. Ch. Friese diplom prezidenta Francie a insignie u příležitosti povýšení na důstojníka nejvyššího francouzského vyznamenání Řádu Čestné legie. Slavnostní ceremoniál se uskutečnil za přítomnosti četných hostů v Buguoyském paláci v Praze, v sídle velvyslanectví Francie v ČR.

Blahopřejeme
Předsednictvo a sekretariát ČLS JEP